Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension

Hypertension Research

Volumn 28, Issue 3, 2005, Pages 223-227

  Nishio, Shinichiro ^a   Watanabe, Hiroshi ^a   Kosuge, Kazuhiro ^a   Uchida, Shinya ^a   Hayashi, Hideharu ^a   Ohashi, Kyoichi ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Amlodipine; Drug interaction; Hypercholesterolemia; Simvastatin

Indexed keywords

AMLODIPINE; CHOLESTEROL; CYTOCHROME P450 3A4; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; DRUG ACTIVITY; DRUG DETERMINATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; PROSPECTIVE STUDY; TRIACYLGLYCEROL BLOOD LEVEL;

ADMINISTRATION, ORAL; AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; DRUG INTERACTIONS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SIMVASTATIN;

EID: 20444503924     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.28.223     Document Type: Article

References (36)

1. Gould KL, Casscells SW, Buja LM, Goff DC: Non-invasive management of coronary artery disease. Report of a meeting at the University of Texas Medical School at Houston. Lancet 1995; 346: 750-753.
2. Shepherd J: Preventing coronary artery disease in the West of Scotland: implications for primary prevention. Am J Cardiol 1998; 82: 57T-59T.
3. Tonkin AM: Management of the long-term intervention with pravastatin in ischaemic disease (LIPID) study after the scandinavian simvastatin survival study (4S). Am J Cardiol 1995; 76: 107C-112C.
4. Matsubara K, Yamamoto Y, Sonoyama K, et al: Current status of lipid management of hypertensive patients. Hypertens Res 2003; 26: 699-704.
5. Minami M, Atarashi K, Ishiyama A, Hirata Y, Goto A, Omata M: Effects of cholesterol-lowering therapy on pressor hyperreactivity to stress in hypercholesterolemic patients. Hypertens Res 2003; 26: 273-280.
6. Wood D: Asymptomatic individuals - risk stratification in the prevention of coronary heart disease. Br Med Bull 2001; 59: 3-16.
7. Gotto AM Jr: Risk factor modification: rationale for management of dyslipidemia. Am J Med 1998; 104 (Suppl 1): 6S-8S.
8. Williams D, Feely J: Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002; 41: 343-370.
9. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary artery disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
10. Vickers S, Duncan CA, Chen IW, Rosegay A, Duggan DE: Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug. Drug Metab Dispos 1990; 18: 138-145.
11. Vickers S, Duncan CA, Vyas KP, et al: In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase. Drug Metab Dispos 1990; 18: 476-483.
12. Prueksaritanont T, Gorham LM, Ma B, et al: In vitro metabolism of simvastatin in humans: identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos 1997; 25: 1191-1199.
13. Neuvonen PJ, Kantola T, Kivisto KT: Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998; 63: 332-341.
14. Kantola T, Kivisto KT, Neuvonen PJ: Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 1998; 64: 177-182.
15. Hsyu PH, Schultz-Smith MD, Lillibridge JH, Lewis RH, Kerr BM: Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Antimicrob Agents Chemother 2001; 45: 3445-3450.
16. Sutton D, Butler AM, Nadin L, Murray M: Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites. J Pharmacol Exp Ther 1997; 282: 294-300.
17. Jones DR, Gorski JC, Hamman MA, Mayhew BS, Rider S, Hall SD: Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation. J Pharmacol Exp Ther 1999; 290: 1116-1125.
18. Watanabe H, Kosuge K, Nishio S, et al: Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. Life Sci 2004; 76: 281-292.
19. Kato J, Aihara A, Kikuya M, et al: Risk factors and predictors of coronary arterial lesions in Japanese hypertensive patients. Hypertens Res 2001; 24: 3-11.
20. Ogihara T, Hiwada K, Morimoto S, et al: Guidelines for treatment of hypertension in the elderly - 2002 revised version - . Hypertens Res 2003; 26: 1-36.
21. Fukui T, Rahman M, Hayashi K, et al: Candesartan antihypertensive survival evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: rationale, design, and methods. Hypertens Res 2003; 26: 979-990.
22. Abernethy D R: Pharmacokinetics and pharmacodynamics of amlodipine. Cardiology 1992; 80 (Suppl 1): S31-S36.
23. Kinnard DR, Harris M, Hossack KF: Amlodipine in angina pectoris: effect on maximal and submaximal exercise performance. J Cardiovasc Pharmacol 1988; 12 (Suppl 7): S110-S113
24. Hansson L, Hedner T, Lund-Johansen P, et al: Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356: 359-365.
25. Yamamoto Y, Sonoyama K, Matsubara K, et al: The status of hypertension management in Japan in 2000. Hypertens Res 2002; 25: 717-725.
26. Eguchi K, Kario K, Shimada K: Differential effects of a long-acting angiotensin converting enzyme inhibitor (temocapril) and a long-acting calcium antagonist (amlodipine) on ventricular ectopic beats in older hypertensive patients. Hypertens Res 2002; 25: 329-333.
27. Meredith PA, Elliott HL: Clinical pharmacokinetics of amlodipine. Clin Pharmacokinet 1992; 22: 22-31.
28. Abernethy DR: The pharmacokinetics profile of amlodipine. Am Heart J 1989; 118: 1100-1103.
29. Kuramoto K, Ichikawa S, Hirai A, Kanada S, Nakachi T, Ogihara T: Azelnidipine and amlodipine: a comparison of their pharmacokinetics and effects on ambulatory blood pressure. Hypertens Res 2003; 26: 201-208.
30. Guengerich FP, Brian WR, Iwasaki M, Sari MA, Baarnhielm C, Berntsson P: Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4. J Med Chem 1991; 34: 1838-1844.
31. Katoh M, Nakajima M, Shimada N, Yamazaki H, Yokoi T: Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol 2000; 55: 843-852.
32. Friedeward WT, Levy RI, Fredrickson DS: Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
33. Arnadottir M, Eriksson LO, Thysell H, Karkas JD: Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin. Nephron 1993; 65: 410-413.
34. Josefsson M, Zackrisson AL, Ahlner J: Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers. Eur J Clin Pharmacol 1996; 51: 189-193.
35. Prueksaritanont T, Vega JM, Zhao J, et al: Interactions between simvastatin and troglitazone or pioglitazone in healthy subjects. J Clin Pharmacol 2001; 41: 573-581.
36. Ma B, Prueksaritanont T, Lin JH: Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos 2000; 28: 125-130.